|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted, a linker-drug discovery platform. The company's primary focus is on treatments for rare diseases. Its product pipeline includes CAT-1004, an oral small molecule for the treatment of Duchenne muscular dystrophy, CAT-2054 for the treatment of hypercholesterolemia and CAT-4001 which is used for the treatment of rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.
CATB $7.30 -0.16 (-2.14%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
EPS -0.62 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend Pay Date --
Dividend History --
This list of trending stocks may change throughout the trading day.
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.